Xerava 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IAIN/0024 
B.II.b.2.c.1 - Change to importer, batch release 
11/05/2023 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
amended 
on 
Annex II and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
R/0023 
Renewal of the marketing authorisation. 
23/02/2023 
12/04/2023 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Xerava in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
eravacycline 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
29/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202202 
eravacycline 
IB/0021/G 
This was an application for a group of variations. 
21/07/2022 
n/a 
B.II.b.z - Change in manufacture of the Finished 
Product - Other variation 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IA/0020/G 
This was an application for a group of variations. 
30/05/2022 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
10/03/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
eravacycline 
IB/0017/G 
This was an application for a group of variations. 
26/10/2021 
n/a 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
variation 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
eravacycline 
II/0012 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
08/07/2021 
29/06/2022 
SmPC 
new quality, preclinical, clinical or pharmacovigilance 
data 
IAIN/0016/G 
This was an application for a group of variations. 
09/06/2021 
29/06/2022 
SmPC, Annex 
II, Labelling 
and PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IAIN/0015 
B.II.b.1.a - Replacement or addition of a 
10/05/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
T/0013 
Transfer of Marketing Authorisation 
08/04/2021 
16/04/2021 
SmPC, 
Labelling and 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
11/03/2021 
n/a 
PRAC Recommendation - maintenance 
/202008 
eravacycline 
PL 
X/0009 
Annex I_2.(c) Change or addition of a new 
10/12/2020 
11/02/2021 
SmPC, Annex 
strength/potency 
II, Labelling 
and PL 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202002 
eravacycline 
IB/0008 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
27/03/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
12/03/2020 
n/a 
PRAC Recommendation - maintenance 
/201908 
eravacycline 
PSUSA/10718
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
/201902 
eravacycline 
IB/0006 
C.I.11.z - Introduction of, or change(s) to, the 
06/06/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
25/04/2019 
28/02/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0003 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
15/04/2019 
n/a 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0002 
B.I.b.1.h - Change in the specification parameters 
28/03/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
IB/0001 
B.II.e.5.a.2 - Change in pack size of the finished 
04/03/2019 
28/02/2020 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
